MARTINSRIED (dpa-AFX) - MorphoSys AG (MPSYY.PK) said its unit for research and diagnostic antibodies, AbD Serotec, would launch a series of novel anti-drug antibodies or ADAs. Starting with the recent launch of fully human, recombinant antibodies binding Rituximab and Trastuzumab, AbD Serotec intends to expand this product category with antibodies against Alemtuzumab, Bevacizumab, Infliximab, Ustekinumab, and Adalimumab in the near future.
Other anti-drug antibodies can be requested as part of the custom antibody service of AbD Serotec.
The Human Combinatorial Antibody Library can deliver highly specific, high-affinity monoclonal antibodies against any given antibody drug with unprecedented success rates. The highly specific HuCAL ADAs are developed solely in vitro, pre-adsorbed against any available controls and human serum.
Copyright RTT News/dpa-AFX
© 2012 AFX News
